The Rockville-based company, an anticipated SPAC merger of American Gene Technologies HIV business and a 10x Capital Venture Acquisition Corp. III, will list on the New York Stock Exchange under the ticker symbol HIV. The company will have a valuation of $500 million. Funds will be used to advance clinical development of Addimmune’s cell therapy for HIV.
5 Questions With Natalie Ferguson, Artist and Creative Marketing Specialist, American Gene Technologies International, Inc. 1. What did you want to be when you grow up? How’d you get from [….]
Why the First Clinical Cure for HIV Will Likely be Developed in Maryland By Chris Frew | September 18, 2023 As was true in the 1980s, Maryland’s DNA Valley remains [….]
American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy By Alex KeownJune 13, 2023 American Gene Technologies (AGT) is one step closer to making history with a [….]
American Gene Technologies Spins Off Addimmune as a Separate Company With a Focus on Curing HIV By Alex KeownJune 9, 2023 Powered by promising Phase I results from its HIV [….]
5 Questions With Layla Ghaffari, Associate Scientist at American Gene Technologies June 6, 2023 “5 Questions With…” is a recurring BioBuzz series where we reach out to interesting people to [….]
Karen McCord Hired as Chief of Staff for American Gene Technologies
Kenneth G. Hadley Joins American Gene Technologies® as People and Culture Manager
You likely know AGT best from their ongoing work to develop a potential HIV cure. Their lead candidate, AGT103-T, is currently in a Phase 1 trial and has shown encouraging data thus far both in patient safety and T cell responses. The company is currently planning for Phase 2.
Curing HIV is an expensive endeavor, and under Sabrina Campbell’s watchful eye, an innovative service is funding the gene therapy trial that may lead to the end of the HIV epidemic. At the beginning of the COVID-19 pandemic, there was a shortage of PCR testing, which prompted American Gene Technologies® to open its own laboratory to bridge supply and demand. Every dollar of profit from the COVID-19 PCR tests performed in the clinical laboratory pays for the HIV Cure Program’s Phase 1 human trial. With such a critical responsibility, the clinical laboratory must operate uninterrupted, which is why we’re thrilled to highlight Sabrina Campbell, the lab manager who’s aiding a potential HIV cure with COVID-19 testing revenue.
